1,803 reports of this reaction
3.5% of all DEFERASIROX reports
#3 most reported adverse reaction
SICKLE CELL ANAEMIA WITH CRISIS is the #3 most commonly reported adverse reaction for DEFERASIROX, manufactured by Novartis Pharmaceuticals Corporation. There are 1,803 FDA adverse event reports linking DEFERASIROX to SICKLE CELL ANAEMIA WITH CRISIS. This represents approximately 3.5% of all 50,952 adverse event reports for this drug.
Patients taking DEFERASIROX who experience sickle cell anaemia with crisis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SICKLE CELL ANAEMIA WITH CRISIS is moderately reported among DEFERASIROX users, representing a notable but not dominant share of adverse events.
In addition to sickle cell anaemia with crisis, the following adverse reactions have been reported for DEFERASIROX:
The following drugs have also been linked to sickle cell anaemia with crisis in FDA adverse event reports:
SICKLE CELL ANAEMIA WITH CRISIS has been reported as an adverse event in 1,803 FDA reports for DEFERASIROX. This does not prove causation, but indicates an association observed in post-market surveillance data.
SICKLE CELL ANAEMIA WITH CRISIS accounts for approximately 3.5% of all adverse event reports for DEFERASIROX, making it one of the most commonly reported side effect.
If you experience sickle cell anaemia with crisis while taking DEFERASIROX, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.